Topic: combination therapy
The response rate was lower in the ONCOS-102 arm than the control cohort, but Targovax saw positives elsewhere.
An engineered vaccinia virus carrying two cytokines that stimulate anti-cancer responses prompted tumor regression in mouse models of three cancers.
The deal gives BeiGene the chance to combine Leap’s anti-DKK1 antibody with its recently approved anti-PD-1 checkpoint inhibitor.
Lowering neutrophil levels in mouse models of non-small cell lung cancer improved responses to PD-1 inhibitors, a Fred Hutchinson team discovered.
Just a week after posting strong data at SABCS, Seattle Genetics has nabbed the coveted FDA breakthrough label for its drug.
Gilead's NASH prospects firsocotat and cilofexor failed to move the needle on liver scarring in a phase 2 study, on their own or in combination.
At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.
The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.
Combining AZ's MCL1 inhibitor AZD5991 with existing MEK or BRAF inhibitors could kill melanoma cells more effectively, scientists found.
The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.